Unresectable Pancreatic Cancer clinical trials

Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation

This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.

HER3-DXd for advanced solid tumors after prior treatment

This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.

Understanding New Cachexia Subtypes Through Observational Epidemiological Research

AB801 with Chemotherapy and Immunotherapy for Bile Duct or Pancreatic Cancer

This study tests a new drug called AB801 combined with standard chemotherapy and immunotherapy for advanced bile duct cancer (cholangiocarcinoma) or pancreatic cancer. The goal is to see if this combination can shrink tumors and help patients live longer.

Vaccine for advanced liver, bile duct, or pancreatic cancer

This trial is testing an investigational vaccine (YMN-136) for people with advanced liver, bile duct, or pancreatic cancer that has not responded to standard treatments or is not tolerated. The vaccine aims to help your immune system fight the cancer. It may be an option if standard treatments have failed.

Carbon ion radiation for locally advanced pancreatic cancer

This trial tests a type of radiation that uses carbon ions to treat pancreatic cancer that can’t be removed with surgery but has not spread to distant organs. It may help shrink or control the tumor while limiting radiation side effects to nearby organs.

Maintenance therapy using combination immunotherapy for pancreatic cancer

This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.

Study of a medicine to prevent low white blood cells from chemo

This trial tests a medicine (tripegfilgrastim) that helps prevent a serious drop in white blood cells (severe neutropenia) caused by certain chemotherapy. It is for people with advanced pancreatic or bile duct cancer who are starting a new treatment.

CAR-NK cell injection for advanced pancreatic cancer

This trial tests a new treatment where CAR-NK cells are injected directly into the pancreatic tumor using an endoscope. It is designed for people with advanced pancreatic cancer that has come back or cannot be removed by surgery.

New drug with chemotherapy for advanced pancreatic cancer

This trial tests a new drug called OT-101 combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination can help shrink or control the cancer better than chemotherapy alone.

IBI343 plus chemo for advanced pancreatic cancer

This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.

Adaptive radiation therapy for advanced pancreatic cancer

This trial tests a new way of giving radiation therapy that adapts to changes in your cancer over time. It is for people with pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body.

Nimotuzumab with chemo and radiation for advanced pancreatic cancer

This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.

New immune cell therapy for advanced pancreatic cancer

This trial tests a new treatment using your own immune cells (called neutrophils) that are loaded with a drug to fight pancreatic cancer that cannot be removed by surgery. It may be an option if standard treatments have stopped working or caused bad side effects.

Surufatinib plus chemotherapy for advanced pancreatic cancer

This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.

Tracking ctDNA for Pancreatic Cancer Before Surgery

This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.

PERT for pancreatic enzyme insufficiency in pancreatic cancer

This trial tests if a pancreatic enzyme replacement therapy (PERT) helps weight loss caused by tumors in the head of the pancreas. It may improve nutrition for people with advanced pancreatic cancer.

Vaccine plus immunotherapy for KRAS-mutant cancers

This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.

Study of ANO31905 plus chemo for CLDN18.2-positive pancreatic cancer

This trial tests a new drug called ANO31905 added to standard chemotherapy for people with advanced pancreatic cancer that has a specific protein called CLDN18.2 on its cells. The study aims to see if the combination works better than chemo alone.

Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers

This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.

T-DXd for advanced HER2-positive solid tumors

This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.

TR-002 for advanced solid tumors and pancreatic cancer

This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.

Entinostat plus ZEN003694 for advanced solid tumors

This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.

Biopsies and FOLFIRINOX for non-metastatic pancreatic cancer

This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.